$ cat ./records/gates-foundation-funds-development-of-pneumosil-most-affordable-p-2008.txt
Gates Foundation Funds Development of PNEUMOSIL — Most Affordable Pneumococcal Vaccine in the World
[RECORD.TXT] · cat --full
In 2008, PATH and the Serum Institute of India began a Gates Foundation-funded collaboration to develop PNEUMOSIL, a 10-valent pneumococcal conjugate vaccine (PCV10) targeting the serotypes responsible for greatest child mortality in Africa, Asia, and Latin America. PNEUMOSIL received WHO prequalification in December 2019 at approximately $2 per dose — roughly 30 percent less than competing PCV products from Pfizer and GSK — and was the first pneumococcal vaccine developed specifically for high-burden rather than high-income markets.
Source: https://www.path.org/our-impact/case-studies/developing-more-affordable-pneumococcal-vaccine/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Grand Challenges Programme Funds Edible and Needle-Free Vaccine Delivery Research
Next →
Gates Foundation Announces $306 Million Agricultural Development Commitment at Davos
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.